## Cytarabine cerebellar neurotoxicity assessment tool

Complete this baseline neurological assessment prior to administering high-dose cytarabine. Neurological assessments should be completed prior to commencing each cytarabine infusion. Increase frequency as clinically indicated.

If the patient scores 1 or above, do not commence the cytarabine infusion and notify the treating team immediately.

| Hospital ID: |  |  |
| :--- | :--- | :--- |
| Surname: |  |  |
| Given names: |  |  |
| Date of birth: | Sex: | AMO: |

Pronouns:
Preferred names:

Treatment protocol:
Date:
Cycle:
Day:

| Cerebellar neurotoxicity assessment chart |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Date \& time |  |  |  |  |  |  |
| Level of consciousness <br> 0 = alert or easily roused <br> 1 = confused or somnolent |  |  |  |  |  |  |
| Orientation-time, place, person$\begin{aligned} & 0=\text { orientated } \\ & 1=\text { disorientated } \end{aligned}$ |  |  |  |  |  |  |
| Speech pattern $\begin{aligned} & 0=\text { clear } \\ & 1=\text { prolonged separation } \\ & \text { of syllables } \end{aligned}$ | - | - | - |  | - | - |
| Gait - ability to walk heel to toe in a straight line $\begin{aligned} & 0=\text { steady } \\ & 1=\text { unsteady/stilting/shuffling } \end{aligned}$ | - | - | - |  | - | - |
| Handwriting <br> 0 = unchanged from previous assessment(s) <br> 1 = deviation from previous assessment(s) |  |  |  |  |  |  |
| Nystagmus <br> $0=$ no nystagmus <br> 1 = nystagmus present | Ask the patient to follow your finger with their eyes (keeping head still). Start with your finger centred in front of the patient. Move your finger to the right, centre, left, centre, upward centre, downward, centre. Assess for rhythmic beats and note direction of nystagmus for each eye position. |  |  |  |  |  |
| $\begin{aligned} & \mathrm{L}=\text { left } \\ & \mathrm{R}=\text { right } \\ & \mathrm{C}=\text { centre } \end{aligned}$ |  |  |  |  |  |  |
| $\begin{aligned} & \mathrm{U}=\text { upward } \\ & \mathrm{D}=\text { downward } \end{aligned}$ | - | - | - | - | - | - |

Romberg test
$0=$ steady (-ve)
$1=$ unsteady/loses balance (+ve)

You are observing to see if the patient requires vision to stand steadily, unaided:
Ask patient to stand with feet together, eyes open and hands by the sides. Ask patient to close eyes for 60 seconds. Observe ability to maintain upright posture. Note: undertake risk assessment prior to performing test, to ensure patient does not sustain injury.

## Upper extremity coordination

## Rapid alternating

 movements (RAMs)$0=$ smoothly
$1=$ clumsy/awkward

## Point to point testing

0 = smoothly
1 = clumsy/awkward

Ask the patient to place one hand on their thigh, and then rapidly turn it over, placing the back of the hand on the same place. Ask them to repeat it rapidly for 10 seconds.

| L |  |  |  |  |  |
| :--- | :--- | :--- | :--- | :--- | :--- |
| R |  |  |  |  |  |

Ask patient to touch your index finger and then their nose, alternating several times. Move your finger so the patient has to extend their arm.

| L |  |  |  |  |  |
| :--- | :--- | :--- | :--- | :--- | :--- |
| R |  |  |  |  |  |

Ask patient to tap your hand as quickly as possible with the ball of their foot, alternating feet.

| L |  |  |  |  |  |
| :--- | :--- | :--- | :--- | :--- | :--- |
| R |  |  |  |  |  |

Point to point testing

Ask patient to place one heel on opposite knee and then run it down the shin to the great toe. Assess both feet.
$0=$ smoothly
$1=$ clumsy/awkward

1 = clumsy/awkward

Assessor's signature
\& designation:

## Handwriting assessment

Date Time Patient handwriting sample

## E: feedback@eviq.org.au

W: eviq.org.au
© Cancer Institute NSW. ID 475. Version 7. Last reviewed February 2024. This document reflects what is currently regarded as safe practice. While every effort has been made to ensure the accuracy of the contents at the time of publication, the Cancer Institute NSW does not accept any liability, with respect to loss, damage, injury, or expense arising from any such errors or omission in the contents of this work. Any reference throughout the document to specific pharmaceuticals and/or medical products as examples does not imply endorsement of any of these products. See www.eviq.org.au for our full disclaimer and any updates.

